BioAge Labs director receives 22,000 stock options
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioAge Labs, Inc. director Michael H. Davidson received a grant of stock options covering 22,000 shares of common stock. These options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues serving the company through that vesting date. Following this grant, Davidson holds 22,000 stock options directly.
Insider Trade Summary
Grant/Award: 22,000 shares
Grant/Award
1 txn
Insider
Davidson Michael H.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 22,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 22,000 options (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 22,000 options (Direct)
Footnotes (1)
- F1. The entire option award shall vest on the earlier of: (i) the date of the next annual meeting of the Issuer's stockholders or (ii) the one year anniversary of the grant date, subject to the reporting person's continued service to the Issuer on the applicable vesting date.
Key Figures
Options granted: 22,000 options
Exercise price: $15.48 per share
Expiration date: June 9, 2036
+1 more
4 metrics
Options granted
22,000 options
Stock Option (Right to Buy) grant to director
Exercise price
$15.48 per share
Strike price for option grant
Expiration date
June 9, 2036
Option term end date
Post-grant derivative holdings
22,000 options
Total stock options following transaction
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, vest, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "15.4800""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-09T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"The entire option award shall vest on the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
grant date financial
"the one year anniversary of the grant date"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BioAge Labs (BIOA) director Michael H. Davidson report on this Form 4?
Michael H. Davidson reported receiving a grant of stock options for 22,000 shares of BioAge Labs common stock. The options were awarded as compensation and give him the right to buy shares at a fixed exercise price in the future, subject to vesting.
How many BioAge Labs (BIOA) stock options were granted to Michael H. Davidson?
He was granted stock options covering 22,000 shares of BioAge Labs common stock. This entire grant is currently unexercised and represents his total derivative holdings reported after the transaction, according to the filing’s post-transaction share balance.
What is the exercise price and expiration date of Michael H. Davidson’s BIOA options?
The stock options have an exercise price of $15.48 per share and expire on June 9, 2036. This means he can choose to buy shares at $15.48 any time before that expiration date, once the options vest.
When do Michael H. Davidson’s BioAge Labs (BIOA) options vest?
The entire option award vests on the earlier of the next annual meeting of BioAge Labs stockholders or the one-year anniversary of the grant date. Vesting is contingent on Davidson’s continued service to the company through the applicable vesting date.
Is Michael H. Davidson’s BIOA option grant an open-market purchase or a compensation award?
The transaction is a compensation-related award, not an open-market purchase. It is coded as a grant or award acquisition, with zero purchase price at grant and a set exercise price of $15.48 per share for future potential exercises.
How is Michael H. Davidson’s ownership in BioAge Labs (BIOA) classified after this option grant?
After the grant, Davidson directly holds 22,000 stock options linked to BioAge Labs common stock. The filing classifies this as direct ownership, meaning the options are held in his own name rather than through an intermediary entity or trust.
AI-generated analysis. How Rhea-AI works. Not financial advice.
